HTA Council Recommendation (as of 29 April 2025) The HTA Council positively recommends the government financing of Factor VIII Inhibitor bypassing activity for treatment of bleeding events for hemophilia B patients with inhibitors. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Plasma-derived Coagulation Factor VIII for treatment of bleeding episodes in the pediatric population with hemophilia A
HTA Council Recommendation (as of 29 April 2025) The HTA Council positively recommends the government financing of Plasma-derived Coagulation Factor VIII for treatment of bleeding episodes in the pediatric population with hemophilia A. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page
Pancreatin for Pancreatic Exocrine Insufficiency (PEI) in adults with pancreatic cancer
HTA Council Recommendation (as of 08 April 2025) The HTA Council positively recommends the government financing of Pancreatin for pancreatic exocrine insufficiency (PEI) in adults with pancreatic cancer (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page
Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding episodes in the pediatric population with hemophilia A
HTA Council Recommendation (as of 29 April 2025) The HTA Council positively recommends the government financing of Plasma-derived Coagulation Factor VIII for prophylaxis/prevention of bleeding episodes in the pediatric population with hemophilia A. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page
Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more
HTA Council Recommendation (as of 08 April 2025) The HTA Council positively recommends the government financing of Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more. (See below for more details) Relevant Information Evidence and Relevant Documents continue reading : Pyronaridine tetraphosphate + Artesunate for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more